logo
Share SHARE
FONT-SIZE Plus   Neg

Ryanair Demands OFT Explanation Regarding BA/BMI Merger Deal - Quick Facts

Ryanair (RYAAY,RYA.L) called on the Office of Fair Trading, or OFT, to explain their decision this week not to ask the European Commission to refer the BA/British Midland merger back to the OFT for assessment, which runs contrary to the OFT's previous decision to attempt to review the European Commission's ruling on Ryanair's failed 2006 offer for Aer Lingus, which the OFT is attempting to investigate, despite the fact that it is out of time to do so.

Ryanair's Michael O'Leary said,

"The OFT now admits that the European Commission is "best placed" to consider these airline mergers, and as a result, the OFT has decided not to review BA's acquisition of British Midland. Given this admission, the OFT and its Irish boss John Fingleton should explain precisely why six years after Ryanair's failed takeover of an Irish airline, Aer Lingus, was prohibited by the European Commission, it now wishes to re-investigate the European Commission's decision not to force Ryanair to dispose of its 29% stake in Aer Lingus..."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Justice Department, in the antitrust trial against the proposed Aetna- Humana Merger, argued that the merger would harm senior citizens who buy private Medicare plans. The U.S. Department of Justice stated that the merger would also harm consumers who buy plans on Affordable Care Act marketplaces, reports said. However, healthcare insurers Aetna And Humana defended their proposed merger.. Telecommunications firm Sprint has extended its Black Friday unlimited data offer for a limited time, the company said in a statement on Monday. When customers switch at least one line to Sprint and sign up for Unlimited Freedom with AutoPay, they get unlimited data, talk and text starting at just $20 per month/line for a family of five until January 31, 2018. Shares of Cerecor Inc. (CERC) plunged over 13% on Monday on disappointing top-line clinical results from its phase II clinical trial of CERC-501 for smoking cessation.
comments powered by Disqus
Follow RTT